Buoy Health
Buoy Health runs an AI symptom checker that routes patients to the right care.
On the record
Checkpoint: Any new funding round, sale, or wind-down announcement given 5.5 years without a priced raise
The call
Buoy built the symptom checker category, but general AI chatbots and hospital-built tools now do its job for free inside other products.
Buoy Health built a tool that helps patients figure out what might be wrong based on their symptoms, but that same job is now done just as well (or better, according to patients) by free AI chatbots like ChatGPT and Google Gemini. Big hospitals and insurance companies are also building their own symptom checkers instead of paying Buoy, and Buoy has not announced new major customers since 2022 or updated its technology to use modern AI. The company could stay relevant if it either gets bought by a large insurance company, gets new funding, or completely rebuilds itself around the latest AI technology and proves it is winning back hospital contracts.
Why
01
AI pressure: ChatGPT and Gemini. 68% of patients now ask general AI chatbots about symptoms first, skipping dedicated checkers like Buoy entirely. Could AI do the core job? Yes, likely.
02
Bigger players: Mayo Clinic, Kaiser Permanente, Ascension, Mount Sinai, Northwestern Medicine. Health systems are building or buying in-house symptom checkers so patients never leave their sites for Buoy. Could a giant copy it? Yes, easily.
03
What protects it. Existing payer relationships (Cigna, Humana, Optum) from its 2020 raise, if any are still active.
What would change this call
Buoy announces a new priced funding round or is acquired by a payer like Cigna or Optum. Would show investors still see viability despite the 5.5-year funding gap.
Buoy publicly confirms an LLM-native product rebuild or new FDA clearance. Would show it is closing the technology and safety gap versus Ada Health and frontier AI.
A payer (Cigna, Humana, Optum) publicly confirms renewing or expanding its Buoy contract. Would show enterprise customers are staying rather than switching to in-house or AI alternatives.
Buoy publicly confirms an LLM-native product rebuild or new FDA clearance. Would show it is closing the technology and safety gap versus Ada Health and frontier AI.
A payer (Cigna, Humana, Optum) publicly confirms renewing or expanding its Buoy contract. Would show enterprise customers are staying rather than switching to in-house or AI alternatives.
Key numbers
- No priced funding round since Nov 2020 ($37.5M Series C)
- Top-3 diagnosis accuracy: 43.0%, below GPs' 82.1%
- 68% of patients go to AI tools first over search engines
Named risks
- No priced funding round since November 2020, a 5.5-year gap raising cash runway concerns.
- Free general-purpose AI chatbots are displacing Buoy's core consumer symptom-checker traffic.
- No FDA clearance or CE mark, unlike certified rival Ada Health.
- Inconsistent, possibly shrinking headcount and a reported VP departure signal organizational instability.
- No independently confirmed enterprise contract renewal with Cigna, Humana, or Optum since 2020-2022.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| ChatGPT / Gemini | losing to | 68% of patients go to AI chatbots first for symptoms, ahead of search, as of Jul 2026 |
| Ada Health | losing to | Outperformed Buoy on diagnostic accuracy (70.5% vs 43.0%) and safety (97.0% vs 80.0%), study cited Jul 2026 |
| Symptomate | losing to | Higher safe-urgency-advice score (97.8%) than Buoy (80.0%) in independent benchmark, Jul 2026 |
| WebMD | losing to | Mass-market incumbent adding AI-assisted symptom guidance, per Jul 2026 industry report |
| Health systems (Mayo, Kaiser, Ascension, Mount Sinai, Northwestern) | losing to | Building or buying in-house symptom-checker tools instead of licensing, per Jul 2026 report |
| UpToDate (Wolters Kluwer) | contesting | Launched generative AI diagnostic layer 'UpToDate Expert AI' in Sep 2025 for clinicians |
Questions people ask
- Is Buoy Health profitable in 2026?
- No confirmed profitability data exists. Third-party estimates of Buoy's revenue conflict wildly, from roughly $4.5M (2022 estimate) to $18.5M, and none are independently verified. Buoy has not disclosed financials publicly, and no priced funding round has been reported since its $37.5M Series C closed in November 2020.
- Could ChatGPT or Gemini replace Buoy Health's symptom checker?
- Largely yes. A July 2026 Corporate Insight report found 68% of patients now go to AI chatbots first for health questions, ahead of search engines at 56%, and directly benchmarks ChatGPT and Gemini against dedicated symptom checkers like Buoy, which still runs a traditional ML/NLP engine with no public LLM rebuild since 2022.
- Who owns Buoy Health?
- Buoy Health is privately held, founded in 2014 by CEO Andrew Le MD with Adam Lathram, Eddie Reyes, and Nathanael Ren out of Harvard Innovation Labs. Investors include Cigna Ventures, Humana, Optum Ventures, and Hambrecht Ducera Growth Ventures, per its November 2020 $37.5M Series C round; no acquisition or IPO has occurred as of mid-2026.
- Who is Buoy Health's biggest competitor?
- Ada Health, a CE Class IIa certified medical device, outperformed Buoy on both diagnostic accuracy and safety in an independent clinical benchmark study cited July 2026 (70.5% top-3 accuracy and 97.0% safe-urgency advice versus Buoy's 43.0% and 80.0%). General AI chatbots like ChatGPT and Gemini are also displacing Buoy's consumer traffic.
- Has Buoy Health raised any funding since 2020?
- No priced funding round has been publicly reported since Buoy's $37.5M Series C closed in November 2020, led by Cigna Ventures and Humana at an estimated $200M post-money valuation. That is a 5.5-year funding gap as of mid-2026, with total funding to date around $66.5M.
- Is Buoy Health FDA approved as a medical device?
- No. Buoy Health is not FDA-cleared or CE-marked as a medical device; it positions itself as an information and navigation tool to avoid medical-device certification. Rival Ada Health, by contrast, holds CE Class IIa certification, a regulatory distinction Buoy still lacks as of July 2026.
Timeline
- 2026-07-21Corporate Insight report shows 68% of patients now use AI chatbots first for symptoms, benchmarking Buoy against ChatGPT, Gemini, rivals
- 2025-09UpToDate launches generative AI layer 'UpToDate Expert AI' for clinician differential diagnosis
- 2024-05ZoomInfo employee directory snapshot lists 54 Buoy employees
- 2022-06Buoy reports over 2 million monthly users and launches digital health marketplace with 36+ partners
- 2020-11Buoy closes $37.5M Series C led by Cigna Ventures and Humana, ~$200M post-money valuation
- 2020-11Buoy reports helping over 9 million individuals; clients include Cigna, Humana, Optum, Banner Health
- 2019-08Buoy closes $15M Series B led by Hambrecht Ducera Growth Ventures with Humana, Optum Ventures
- 2014Buoy Health founded by Andrew Le MD and co-founders out of Harvard Innovation Labs, Boston
Revision history
22 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Digital health company Buoy raises $37.5M in Series C funding (2020-11-10)
- Valuation, Funding Rounds & Stock Price
- Buoy - Overview, News & Similar companies (2026-07-06)
- Revenue, Competitors, Alternatives (2022-04-18)
- Cigna, Humana lead $37.5M investment in Buoy Health (2020-11-16)
- What the press says
- Corporate Insight Releases Report on Public Site Symptom Checkers (2026-07-21)
- How accurate are digital symptom assessment apps for suggesting conditions and urgency advice?
- Chat About Symptoms
- Best Symptom Checker and Differential Diagnosis Tools for Clinicians in 2026 (2026-07-02)
- Ada Health -> History (2026-07-22)
- EverybodyWiki Bios & Wiki (2026-07-12)